Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Forte Biosciences ( (FBRX) ) has provided an update.
Forte Biosciences, Inc. has announced a successful $53 million private placement with key institutional investors to advance its lead candidate, FB102, in autoimmune indications. The oversubscribed financing demonstrates strong investor confidence, enabling Forte to further clinical trials and explore additional applications for FB102. With a celiac disease trial underway and other studies planned, Forte anticipates significant clinical milestones in 2025.
Learn more about FBRX stock on TipRanks’ Stock Analysis page.
